ReviewJournal of clinical medicine2021
Opioids and Sickle Cell Disease: From Opium to the Opioid Epidemic.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Pain Control for Sickle Cell Crisis, a Novel Approach? A Retrospective Study.Medicina (Kaunas, Lithuania) · 2023Pooled it
- Digital cognitive behavioral therapy vs education for pain in adults with sickle cell disease.Blood advances · 2024Trial
- Negative Descriptors of Patients With Sickle Cell Disease in the Electronic Health Record.JAMA network open · 2026Article
- Cost-Effectiveness Analysis of Crizanlizumab in Sickle Cell Disease in Iran.Iranian journal of medical sciences · 2025Article
- Sickle cell disease and opioid overdose outcomes in the United States: a nationwide analysis.Annals of hematology · 2025Article
- The Evaluation of Patient-Controlled Analgesia Compared to Standard Opioid Analgesic Therapy in Pain Management Among Patients With Sickle Cell Disease: A Systematic Review and Meta-Analysis Protocol.Health science reports · 2025Article
- Prevalence and factors associated with opioid use disorder among adolescents with sickle cell disease in Mulago hospital, Uganda.Child and adolescent psychiatry and mental health · 2024Article
- The Associations Between Opioid Use Disorder and Healthcare-Related Outcomes in Vaso-occlusive Crisis.Journal of general internal medicine · 2024Article
- Pain specialists in the management of sickle cell disease: a call to action.Pain management · 2024Article
- Predictive Factors for 30-Day Readmission and Increased Healthcare Utilization in Sickle Cell Disease Patients: A Single-Center Comparative Retrospective Study.International journal of general medicine · 2024Article
- Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission.The Lancet. Haematology · 2023Review
- Prevalence of Substance Use Disorders in Sickle Cell Disease Compared to Other Chronic Conditions: a Population-Based Study of Black American Adults.Journal of general internal medicine · 2023Article
- Opioid Use in Patients With Sickle Cell Disease During a Vaso-Occlusive Crisis: A Systematic Review.Cureus · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sickle cell disease (SCD) is an inherited disorder of hemoglobin structure. The clinical effects of the sickle gene are pleiotropic in nature causing multiple phenotypic expressions associated with the various complications of the disease. The hallmark of the disease is pain that could be acute, chronic, nociceptive, or neuropathic that could occur singly or in various combinations. The acute vaso-occlusive painful crisis (VOC) is the most common cause of admissions to the Emergency Department and/or the hospital. Although progress has been made in understanding the pathophysiology of SCD as well as in developing preventive and curative therapies, effective pain management continues to lag behind and depend mostly on the use of opioids. This review describes the history of opioids from the ancient times of opium to the current use of the many controversial opioids. In addition, the major cause of death of patients with SCD is the complications of the disease itself and not the use of opioids. The use of opioids by patients with SCD has been stable over the years. Judicious use of opioids to treat sickle cell pain according to available guidelines could minimize the unnecessary suffering experienced by patients with SCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.